February 4, 2026
We have today announced a strategic investment from Prism Healthcare Group into Mackworth USA, marking an important milestone in our continued growth within the US healthcare market.
The investment accelerates Mackworth USA’s ambitions in one of the fastest-growing healthcare markets globally and further strengthens our position across North America. Becoming part of the Prism Healthcare Group enables us to deepen our capabilities, expand our reach and leverage the group’s scale, expertise and commitment to innovation.
This partnership also supports our pioneering digital service platform, providing new opportunities to differentiate our offering and deliver enhanced value to healthcare providers, distributors and systems throughout the US.
The investment underlines a shared commitment to supporting US manufacturing, while creating opportunities for collaboration, innovation and knowledge-sharing across Prism Healthcare Group’s UK and international operations.
Charley Wallace, CEO of Mackworth USA, says:
“This is a powerful moment for Mackworth USA. Joining Prism Healthcare Group gives us the platform, investment and international reach to accelerate our growth and continue delivering exceptional products to our customers.
“It enables us to strengthen manufacturing in the US, invest further in innovation and position Mackworth USA for long-term success as part of a global healthcare group.”
Jason Leek, CEO of Prism Healthcare Group, adds:
“Mackworth USA is a highly respected business with strong digital capability and a clear growth trajectory. This investment renews and strengthens our presence in the US and reinforces our ability to serve healthcare systems across North America.”
This investment represents a significant step forward for Mackworth USA as we enter a new phase of growth. With the backing of Prism Healthcare Group, enhanced digital capabilities and a continued focus on manufacturing excellence, we are well positioned to support healthcare systems and improve patient outcomes at scale.